LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.54 -5.7

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.52

Max

18.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	614M 331M
Pardavimai	288M 731M
P/E Sektoriaus vid.	55.429 51.415
Pelnas, tenkantis vienai akcijai	3.16
Pelno marža	45.287
Darbuotojai	835
EBITDA	624M 372M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+15.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-279M 2B
Ankstesnė atidarymo kaina	23.24
Ankstesnė uždarymo kaina	17.54

Naujienos nuotaikos

By Acuity

100%

334 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

N/A / 62.47 Palaikymas ir pasipriešinimas

Sarepta Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-29 15:04; UTC

Pagrindinės rinkos jėgos

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

2025-07-21 11:31; UTC

Pagrindinės rinkos jėgos

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-01-26 09:55; UTC

Karštos akcijos

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

2025-11-04 14:39; UTC

Uždarbis

Karštos akcijos

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

2025-11-04 12:45; UTC

Uždarbis

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

2025-08-11 11:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-08-11 11:11; UTC

Uždarbis

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025-07-29 21:11; UTC

Uždarbis

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

2025-07-29 12:14; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-29 11:46; UTC

Uždarbis

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

2025-07-21 12:53; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

2025-07-21 11:17; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

2025-07-21 10:25; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

2025-07-21 09:50; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-21 09:12; UTC

Uždarbis

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025-07-17 16:44; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

2025-07-17 13:48; UTC

Uždarbis

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 10:57; UTC

Uždarbis

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

2025-07-17 09:08; UTC

Karštos akcijos

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025-06-17 09:10; UTC

Karštos akcijos

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-17 08:59; UTC

Karštos akcijos

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025-06-16 08:55; UTC

Karštos akcijos

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Akcijų palyginimas

Kainos pokytis

Sarepta Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

15.85% į viršų

12 mėnesių prognozė

Vidutinis 21.64 USD 15.85%

Aukščiausias 38 USD

Žemiausias 5 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sarepta Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

24 ratings

Pirkti

Laikyti

Parduoti

Remiantis 24 analitikų, pateikusių Sarepta Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 62.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

334 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.